- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579603
Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone.
A secondary objective is to assess the exposure based on PK trough concentration values to nintedanib either given alone or in combination with pirfenidone and to assess the exposure of pirfenidone when combined with nintedanib.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul'S Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2K 3S8
- Concordia Hospital
-
-
-
-
-
Bobigny, France, 93009
- HOP Avicenne
-
Brest, France, 29609
- HOP de la Cavale Blanche
-
Bron cedex, France, 69677
- HOP Louis Pradel
-
Lille, France, 59037
- HOP Calmette
-
Nice, France, 06001
- HOP Pasteur
-
Paris, France, 75018
- HOP Bichat
-
Rennes, France, 35033
- HOP Pontchaillou
-
-
-
-
-
Donaustauf, Germany, 93093
- Klinik Donaustauf
-
Essen, Germany, 45239
- Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
-
Heidelberg, Germany, 69126
- Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
-
-
-
-
-
Catania, Italy, 95124
- A.O.U. Policlinico Vittorio Emanuele
-
Milano, Italy, 20123
- Osp. S. Giuseppe Fatebenefratelli
-
Siena, Italy, 53100
- A.O.U. Senese Policlinico Santa Maria alle Scotte
-
-
-
-
-
Nieuwegein, Netherlands, 3435 CM
- Sint Antonius Ziekenhuis
-
Rotterdam, Netherlands, 3015 CE
- Erasmus Medisch Centrum
-
-
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Western CT Medical Group, P.C.
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Hospital and Clinic
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minnesota Lung Center
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- The Lung Research Center, LLC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Lowcountry Lung and Crit Care
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-5735
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Written informed consent consistent with ICH-GCP(The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use- Good clinical practice) and local laws, signed prior to any study procedures being performed (including any required washout)
- Male or female patients aged greater than or equal to 40 years at visit 1
- Idiopathic Pulmonary Fibrosis (IPF) diagnosis, based upon the ATS (American Thoracic Society)/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Latin American Thoracic Association) 2011 guideline and confirmed by the investigator based on chest high resolution computed tomography (HRCT) scan performed within 12 months of visit 1
- FVC (Forced vital capacity) greater than or equal to 50% of predicted normal at visit 1
Exclusion criteria:
- ALT (Alanine transaminase), AST (Aspartate aminotransferase)> 1.5 fold upper limit of normal (ULN) at visit 1
- Total bilirubin > 1.5 fold ULN at visit 1
- Relevant airways obstruction (i.e. pre-bronchodilator FEV1 (Forced Expiratory Volume in one second)/FVC <0.7) at visit 1
- History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1
- Bleeding Risk: Known genetic predisposition to bleeding, Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin etc) or high dose antiplatelet therapy, History of haemorrhagic central nervous system event within 12 months prior to visit 1, History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1, International normalised ratio (INR) > 2 at visit 1, Prothrombin time and partial thromboplastin time (PTT) > 150% of institutional ULN at visit 1
- Planned major surgery during the trial participation, including lung transplantation,major abdominal or major intestinal surgery.
- History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1
- Severe renal impairment (Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula at visit 1) or end-stage renal disease requiring dialysis
- Treatment with NAC (n-acetylcysteine), prednisone >15 mg daily or >30 mg every 2 days OR equivalent dose of other oral corticosteroids and/or fluvoxamine within 2 weeks of visit 2
- Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other investigational drug within 8 weeks of visit 2
- Previous treatment with pirfenidone
- Permanent discontinuation of nintedanib in the past due to Adverse Events considered drug-related
- Known hypersensitivity to nintedanib, pirfenidone, peanut or soya or to any of the excipients
- A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial
- Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly5 for 28 days prior to and 3 months after nintedanib administration
- Patients not able to understand and follow study procedures including completion of self administered questionnaires without help
- Patients who require dose reduction and/or temporary interruption during the run-in period with nintedanib 150 mg bid
- Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nintedanib
Nintedanib 150 mg bid
|
Nintedanib 150mg bid
|
Experimental: Nintedanib and Pirfenidone
Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
|
Nintedanib 150mg bid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12
Time Frame: Baseline to week 12
|
Percentage of patients with on-treatment gastrointestinal (GI) Adverse events (AEs) (SOC GI disorders) from baseline to week 12. On-treatment AEs were defined as AEs with an onset from the first dose of randomised treatment up to the last dose of randomised treatment (inclusive). |
Baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4
Time Frame: baseline, prior to intake of study medication on week 2 and week 4
|
Predose plasma concentrations at steady state (Cpre,ss) of nintedanib at baseline (Visit 3), Week 2 (Visit 4) and Week 4 (Visit 5)
|
baseline, prior to intake of study medication on week 2 and week 4
|
Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone
Time Frame: Prior to intake of study medication on week 2 and week 4
|
Predose plasma concentrations at steady state (Cpre,ss) of pirfenidone at Week 2 (Visit 4) and Week 4 (Visit 5)
|
Prior to intake of study medication on week 2 and week 4
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Fibrosis
- Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Pirfenidone
- Nintedanib
Other Study ID Numbers
- 1199.222
- 2015-000640-42 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
University of Colorado, DenverWithdrawn
Clinical Trials on Nintedanib
-
Boehringer IngelheimCompletedCarcinoma, HepatocellularJapan
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedHealthyUnited Kingdom
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruiting
-
Wake Forest University Health SciencesBoehringer IngelheimTerminated
-
Boehringer IngelheimCompletedIdiopathic Pulmonary FibrosisSpain, Korea, Republic of, Belgium, Czechia, Australia, Germany, United Kingdom, United States, France, Finland, Japan, Poland, Hungary
-
Boehringer IngelheimActive, not recruitingLung Diseases, InterstitialUnited States, Spain, United Kingdom, Canada, Finland, Norway, Italy, Argentina, Belgium, Brazil, Czechia, France, Greece, Mexico, Poland, Germany, Portugal
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Boehringer IngelheimApproved for marketingIdiopathic Pulmonary FibrosisUnited States
-
Boehringer IngelheimNo longer availableIdiopathic Pulmonary FibrosisBrazil